UAE doctors urge screening from age 10 as youth Type 2 diabetes rises

UAE doctors are calling for diabetes screening from age 10 for overweight children with risk factors, after a US registry study found Type 2 diabetes among under-20s rose from 2.37 to 22.30 cases per 100,000 between 2002 and 2023.

The immediate operational question is in Dubai, where clinics regulated by the Dubai Health Authority (DHA) will see the largest private-sector demand signal. The issue also matters for Department of Health - Abu Dhabi (DOH) providers, Thiqa pathways and Ministry of Health and Prevention (MOHAP)-licensed clinics in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain. The highest-stakes readers are clinic COOs, medical directors and payer teams: screening creates a front-door workflow before the child is a diabetes patient.

What changed in the clinical signal

The National reported on 25 August 2026 that UAE physicians support earlier screening after the Colorado Diabetes Registry study. The 20-year study will be presented at the European Association for the Study of Diabetes meeting in Milan in September 2026. It used diagnosis codes, laboratory results and medication data across health systems.

"Type 2 diabetes is shifting to younger ages," said Dr Brijesh Bharadwaj, department head at NMC Royal Hospital DIP, Dubai.

The article also cited Dr Yasmeen Ajaz, consultant endocrinologist at Medcare Hospital in Al Safa, Dubai, and Dr Amna Kiran Sarwar, specialist endocrinologist at International Modern Hospital Dubai. The doctors pointed to childhood obesity, processed foods, sugary drinks, screen time, insufficient sleep, family history and genetics as relevant risks. The International Diabetes Federation lists the UAE at 20.7% adult diabetes prevalence in 2024, or 1,274,200 adults.

What clinics and payers need to price

The actionable age marker is clear. The American Diabetes Association's 2026 Standards of Care advise risk-based screening for prediabetes or Type 2 diabetes after puberty or after 10 years of age, whichever occurs earlier, for children with overweight or obesity and risk factors. UAE clinics should convert that into a paediatric intake rule, not a marketing campaign.

• Clinical trigger: age 10 or puberty, overweight or obesity, plus family history, maternal gestational diabetes, signs of insulin resistance or high-risk ethnicity.
• Common tests: HbA1c, fasting plasma glucose or oral glucose tolerance test, with urine albumin and lipid testing added when clinically indicated.
• Dubai cash pricing: published online prices on 25 August 2026 included HbA1c at AED 75-99 and fasting glucose at AED 49-75 at Zain Cura, and an at-home HbA1c test at AED 239 through Nabta Health.
• Package pricing: Dubai diabetes or blood-test packages advertised online ranged from AED 149 at MED7 CarePlus to AED 1,400 at CMC Dubai Hospital; many are adult or promotional products, so paediatric eligibility must be checked before quoting.

For CFOs, the margin issue is pathway design. A low-cost HbA1c test can produce a referral cascade to paediatric endocrinology, dietetics, ophthalmology and nephrology. For insurers, including Daman, Thiqa and Sukoon where the member's plan applies, the question is whether screening is billed as prevention, diagnostic work-up or chronic disease management. Clinics should verify network rules, pre-authorisation requirements and excluded wellness packages before launching school-age offers.

Dubai first, then the rest of the UAE

Dubai operators should start with DHA-licensed family medicine, paediatric and endocrinology clinics. The practical change is adding body mass index percentile, family history and maternal gestational diabetes to paediatric triage templates, then creating a follow-up slot within two to four weeks for abnormal HbA1c or fasting glucose results. That timeframe is an operational benchmark, not a regulator deadline.

In Abu Dhabi, DOH-linked prevention infrastructure already exists for adults. The Abu Dhabi Public Health Centre says the IFHAS programme covers Thiqa holders aged 18 to 75 every three years, or more often when a doctor deems it necessary. That does not solve paediatric Type 2 screening. It gives payers and providers a template for recall systems, risk scoring and network routing.

In the northern emirates, MOHAP-licensed clinics have a simpler commercial opportunity and a quality risk. The opportunity is affordable testing tied to family medicine and dietetics. The risk is over-selling broad wellness packages to parents when a targeted paediatric risk assessment may be enough. Operators should publish eligibility, test list, fasting requirements, result timing and referral criteria in plain language.

The next watch point is whether DHA, DOH Abu Dhabi or MOHAP convert physician concern into a formal paediatric screening pathway. Until then, clinic leaders should audit paediatric visits, insurer coverage rules and referral capacity. Patients and operators can use the UAE Open Healthcare Directory to find licensed clinics and providers before booking screening.